Real-time Estimate
Cboe BZX
14:15:45 2024-06-17 EDT
5-day change
1st Jan Change
16.32
USD
+2.61%
+2.23%
+1.59%
Innoviva, Inc.'s Equity Buyback announced on November 9, 2022, has closed with 7,807,887 shares, representing 11.78% for $100 million.
The company closed its plan on April 25, 2024.
Transcript : Innoviva, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM
06-10
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
05-20
MT
Transcript : Innoviva, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM
05-15
Earnings Flash (INVA) INNOVIVA Posts Q1 Revenue $77.5M
05-08
MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
05-08
CI
Innoviva, Inc. Appoints Derek Small to the Board of Directors
05-08
CI
Innoviva, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-08
CI
Innoviva, Inc.'s Equity Buyback announced on November 9, 2022, has closed with 7,807,887 shares, representing 11.78% for $100 million.
04-24
CI
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
04-24
CI
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit
03-04
MT
North American Morning Briefing : Stock Futures -2-
03-04
DJ
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
02-29
CI
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M
02-29
MT
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
02-29
CI
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics
02-06
CI
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing
11-17
MT
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
11-01
CI
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-01
CI
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M
11-01
MT
Innoviva Names Stephen Basso as Finance Chief
23-08-28
MT
Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer
23-08-25
CI
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.
23-08-02
CI
Earnings Flash (INVA) INNOVIVA Reports Q2 Revenue $81M
23-08-02
MT
Innoviva, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-02
CI
Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee
23-07-11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).
More about the company
Last Close Price
15.91
USD
Average target price
16
USD
Spread / Average Target
+0.57%
Consensus
1st Jan change
Capi.
+1.59% 993M +52.39% 791B +40.45% 630B +17.06% 328B +9.20% 298B +17.25% 246B +0.41% 225B +10.22% 218B +5.10% 160B -6.37% 156B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1